Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: May 19, 2023

Abstract Background Ovarian serous cystadenocarcinoma (OSC) is the most common pathological subtype of ovarian cancer (OC) associated with high mortality. Albeit dysregulated mitochondrial metabolism has been implicated OC, role genes in OSC remains unclear. We sought to construct a model based on for prognosis prediction, drug guidance and immune feature analysis OSC. Methods Differentially expressed (DEGs) mitochondrial-related DEGs (MRGs) were identified through Cancer Genome Atlas (TCGA)-OV dataset. Consensus clustering algorithm was applied classify patients into distinct MRGs subtypes. Prognosis-related screened prognosis-related Risk score model, which verified using GSE26193 dataset immunohistochemistry (IHC) staining intensity extent scores MRGs. A visualized nomogram developed predict 1-, 3- 5-year overall survival (OS) response. The correlation subtypes risk subgroups association response infiltration also investigated. Results 341 from TCGA-OV, could be mainly divided two novel prognostic 7-MRGs, including ACOT13 , ACSS3 COA6 HINT2 MRPL14 NDUFC2 NDUFV2 validated via IHC model. Patients low-risk group had significantly longer OS. exhibited good assessment accuracy both training validation datasets. Drug sensitivity indicated that cisplatin, paclitaxel docetaxel more sensitive group; VEGFR inhibitor Axitinib, BRAF inhibitors Vemurafenib SB590885 showed better high-risk moreover, have anti-PD-1 immunotherapy “cluster1” lower than “cluster2” subgroup. More significant infiltrated tumor killing cells (CD8 + T cells) higher M1 / M2 macrophage ratio patients. Conclusions Our 7 MRGs-based huge prospects evaluate guide treatment. favorable closely related anti-tumor cellular infiltration.

Language: Английский

---

Long-Term Temporal Trends in Survival Among Danish Patients with Advanced Cutaneous Melanoma: A Nationwide Follow-Up Study

Clinical Epidemiology, Journal Year: 2023, Volume and Issue: Volume 15, P. 733 - 742

Published: June 1, 2023

Population-based data on survival trends over time among patients with advanced cutaneous melanoma are lacking. We examined changes in mortality for diagnosed from 1980 to 2011 a nationwide historical follow-up study using population-based medical registries Denmark.The population included all Danish an incident diagnosis of (metastatic or unresectable stage IIIA, IIIB, IIIC, IV) (ie, initial at III/IV) between 1980-2011 and who were followed-up until 2013. For each patient, we randomly matched 100 individuals the general sex year birth. Age-standardized rates calculated by calendar overall, 30 days after diagnosis, during 31 364 0-10 years diagnosis. Stratified Cox's proportional hazards regression was used compute hazard ratios.We identified total 1236 123,600 comparison cohort members. observed that standardized dropped 1980s onwards, but remain high (eg, 74.3 248.4 per 1000 person-years 0-30 31-364 respectively, 2008-2011). Compared population, had 10.4-fold increased death follow-up. The highest relative found first following No improvements compared most recent period, thus 2004-2007 2008-2011.Survival Denmark improved 2013 appears have leveled off leading up more widespread introduction newer immuno-oncology therapies.

Language: Английский

---

PET-CT vs brain MRI for the detection of cerebral metastases of melanoma, a 5-year retrospective study

Published: July 17, 2023

What does this study add?• Despite the increasing performance of PET-CT, brain MRI remains most efficient diagnostic tool to detect melanoma cerebral metastases and should always be performed in addition PET-CT patients with high-risk from stage IIC.

Language: Английский

---

Real-world data show improved melanoma survival in Sweden

British Journal of Dermatology, Journal Year: 2023, Volume and Issue: 189(6), P. 650 - 651

Published: Aug. 24, 2023

Journal Article Corrected proof Real-world data show improved melanoma survival in Sweden Get access Magdalena Claeson Conceptualization, Funding acquisition, Writing - original draft, review & editing Department of Dermatology and Venereology, Institute Clinical Sciences, Sahlgrenska Academy, University Gothenburg, SwedenDepartment Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia Email: [email protected] https://orcid.org/0000-0001-5021-323X Search for other works by this author on: Oxford Academic Google Scholar British Dermatology, ljad309, https://doi.org/10.1093/bjd/ljad309 Published: 24 August 2023 history Received: 18 Accepted: 19 typeset: 15 September

Language: Английский

---